#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

What It Covers

Psychiatrist Linus Abrams, with 35 years of clinical experience, challenges the neurotransmitter-only model of mental health by examining how estradiol, testosterone, progesterone, thyroid hormone, and cortisol directly regulate mood, cognition, and psychiatric conditions. The conversation covers bipolar misdiagnosis, treatment-resistant depression, hormonal transitions across the lifespan, and the clinical realities of ketamine and psilocybin therapies.

Key Questions Answered

• •Bipolar vs. Unipolar Misdiagnosis: Prescribing an antidepressant to someone with undiagnosed bipolar II disorder can trigger mood cycling, agitation, racing thoughts, or a mixed state combining depression with physical agitation. The correct first-line approach for bipolar depression is a mood stabilizer — lamotrigine or lithium — not an SSRI. Lamotrigine works effectively as monotherapy for bipolar depression before any antidepressant is considered, reducing the risk of destabilizing the patient's mood architecture entirely.
• •Estradiol as a Brain System Modulator: Estradiol is not merely a reproductive hormone — it regulates serotonin synthesis via tryptophan hydroxylase, dopamine via tyrosine hydroxylase, acetylcholine via choline acetyltransferase, and also modulates GABA, NMDA, and glutamate systems. It binds to membrane receptors and estrogen response elements within neuronal DNA. When estradiol declines during perimenopause or menopause, the resulting multi-domain impairment — mood, cognition, anxiety — reflects the loss of this foundational regulatory architecture, not simply a hormonal deficiency.
• •Free T4 Over TSH for Psychiatric Assessment: Standard TSH testing misses clinically relevant thyroid insufficiency in depressed patients. A TSH in the upper half of the normal range (roughly 2.5–5.0) can still indicate suboptimal thyroid function. Linus Abrams prioritizes free T4 and free T3 levels instead. Patients with low-normal free T4 and depression often respond well to T4 and T3 combination supplementation. In treatment-resistant unipolar depression, T3 alone — starting at 2.5–5 mcg twice daily, titrated up to 25 mcg twice daily — has produced meaningful symptom relief after multiple antidepressant failures.
• •SSRI Side Effect Profile and Dopamine Suppression: SSRIs increase serotonin but can suppress dopamine and norepinephrine through receptor feedback mechanisms, producing what patients describe as feeling better but lacking vitality or drive. This is especially problematic for patients with subclinical ADHD, where dopamine is already low. SNRIs balance serotonin and norepinephrine reuptake inhibition, reducing cognitive dulling. For conditions requiring maximal serotonergic signal — OCD and PTSD specifically — SSRIs remain preferable because aggressive serotonin amplification produces better outcomes than a balanced approach.
• •Hormonal Fluctuation, Not Absolute Levels, Drives Psychiatric Vulnerability: PMDD and postpartum depression are driven by the rate of hormonal change rather than the absolute hormone level. Progesterone is flat during the follicular phase, rises post-ovulation, then crashes before menstruation — and it is that drop in allopregnanolone (a progesterone metabolite) that triggers symptoms in susceptible women. Postpartum, estradiol drops from roughly 30,000 pg/mL to approximately 30 pg/mL within 24–48 hours. Zuranolone, a synthetic oral allopregnanolone analog, is now the targeted treatment for acute severe postpartum depression.
• •Testosterone's Role in Male Cognitive and Mood Function: Testosterone modulates dopamine through both the mesolimbic pathway — governing reward salience and motivation — and the mesocortical pathway — governing executive function and working memory. Declining testosterone in men produces ADHD-like symptoms, cognitive dulling, and reduced reward drive before libido changes become obvious. Clomiphene raises peripheral testosterone numbers but consistently underdelivers symptom relief, likely because it blocks central estrogen and testosterone receptors at the hypothalamus, depriving the brain of the very hormones it needs despite normalizing blood values.
• •Ketamine as a Bridge, Not a Solution: Ketamine blocks NMDA receptors, triggering a glutamate surge, mTOR pathway activation, and rapid synaptic remodeling — producing neuroplasticity within hours. This makes it effective for acute suicidal ideation, where it can reduce crisis-level risk quickly enough to avoid hospitalization. However, Linus Abrams uses it primarily as a bridge while identifying a longer-term pharmacologic solution, as sustained remission from ketamine alone is uncommon in his clinical experience. Recreational use without supervision carries serious risk given its dissociative anesthetic properties and unpredictable psychological effects.